Regorafenib - New drug. Metastatic colorectal cancer in treatment failure: May prolong survival by a few weeks

Prescrire International

Volumn 23, Issue 145, 2014, Pages 8-11

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMYLASE; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; REGORAFENIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE KIDNEY FAILURE; AMYLASE BLOOD LEVEL; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BODY WEIGHT DISORDER; BREAST FEEDING; BREAST MILK; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CARDIOVASCULAR MALFORMATION; COLORECTAL CARCINOMA; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG TREATMENT FAILURE; DRY SKIN; DYSPHONIA; ELECTROLYTE DISTURBANCE; EPISTAXIS; FATIGUE; FERTILITY; FEVER; HAIR LOSS; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATURIA; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY MALFORMATION; LEUKOENCEPHALOPATHY; LIVER INJURY; LOSS OF APPETITE; METASTATIC COLORECTAL CANCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECTUM HEMORRHAGE; SINUS BRADYCARDIA; SKELETON MALFORMATION; SPONTANEOUS ABORTION; STEVENS JOHNSON SYNDROME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VEIN THROMBOSIS; WEIGHT REDUCTION; WOUND HEALING; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DRUG INTERACTION; GASTROINTESTINAL DISEASE; METASTASIS; MORTALITY; PATHOLOGY; SKIN DISEASE; TREATMENT FAILURE;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; SKIN DISEASES; TREATMENT FAILURE;

EID: 84893808862     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Prescrire Rédaction "Cancer colorectal, en bref"Idées-Forces Prescrire updated February 2012: 5 pages.
2. US FDA - CDER "Application number 203085Orig1s000 - Statistical review(s)" 30 August 2012: 21 pages.
3. "Onyx and Bayer settle dispute" Scrip 21 October 2011: 10.
4. US FDA "Full prescribing information - Stivarga"May 2013: 17 pages.
5. ANSM "Commission d'AMM du 25 October 2012 - Verbatim" posted on the ANSM website 17 December 2012: 20 pages.
6. US FDA - CDER "Application number 203085Orig1s000 - Medical review(s)" 7 September 2012: 69 pages.
7. US FDA - CDER "Application number 203085Orig1s000 - Summary review" 20 September 2012: 23 pages.
8. ANSM "RCP-régorafénib" December 2012: 15 pages.
9. Grothey A et al. "Regorafenib monotherapy for previously treated metastatic colorectal cancer (Correct): an international, multicentre, randomised, placebo-controlled, phase 3 trial" Lancet 2013; 381: 303-312.
10. US FDA - CDER "Application number 203085Orig1s000 - Risk assessment and risk mitigation review(s)" 28 August 2012: 8 pages.
11. "Asian subjects with metastatic colorectal cancer treated with regorafenib or placebo after failure of standard therapy". www.clinicaltrials.gov.fr accessed 19 November 2012: 10 pages.
12. Prescrire Editorial Staff "Pharmacogenetics and personalised medicine: maintain a critical approach Pharmacogenetics and personalised medicine: maintain a critical approach" Prescrire Int 2013; 22 (139): 161-163.
13. Prescrire Editorial Staff "Panitumumab adjunctive therapy. No place in either first- or second-line treatment of metastatic colorectal cancer " Prescrire Int 2013; 22 (138): 120.